Jakubowicz, D.J., et al. (2001) Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in polycystic ovary syndrome. Journal Clinical Endocrinology Metabolism, 86, 1126-1133. doi:10.1210/jc.86.3.1126

has been cited by the following article:

• TITLE: Defining prediabetes in polycystic ovarian syndrome

  AUTHORS: Mark P. Trolice

  KEYWORDS: Polycystic Ovarian Syndrome; Prediabetes; Impaired Glucose Tolerance; Impaired Fasting Glucose; Type 2 Diabetes

  JOURNAL NAME: Open Journal of Obstetrics and Gynecology, Vol.1 No.2, June 30, 2011

  ABSTRACT: Objective: The article will review the associations between Prediabetes (PD) and Polycystic Ovarian Syndrome (PCOS) and present factors that decrease the progression of PD into type 2 diabetes mellitus (T2DM).Metformin will also be examined for its role in ovulation induction, pregnancy and ameliorating the metabolic syndrome. Study Design: Medline search. Methods of study: Keyword search: Prediabetes (PD), Polycystic Ovarian Syndrome (PCOS), Metformin, Glucose Tolerance Test (GTT), Type 2 Diabetes Mellitus. Results: As the most common endocrinopathy during the reproductive years, PCOS has a genetic multifactorial inheritance and is associated with a high risk of insulin resistance. The use of metformin has shown mixed results in this patient population as a therapy to improve ovulation function and the metabolic syndrome and showed no definitive reduction in the rate of miscarriage. PCOS patients are significantly predisposed to PD and T2DM. Conclusion: Lifestyle changes such as weight loss and physical activity reduce the progression of PD into T2DM in PCOS patients. The new AACE and ADA guidelines establish simplified methods of screening and treating PD. The role of metformin remains undefined in the infertile PCOS patient.